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Background: To evaluate changes in health-related quality of life (HRQOL) in different sub-groups of a cohort of
patients with typical atrial flutter (AFL) treated with cavotricuspid isthmus (CTI) radiofrequency catheter ablation.
Methods: 95 consecutive patients due to undergo CTI ablation were enrolled in a study involving their completion
of two SF-36 HRQOL questionnaires, before ablation and at one-year follow-up.
Results: 88 of the initial 95 patients finished the study. Regardless of whether patients experienced atrial fibrillation
(AF) during follow-up, a statistically significant improvement in HRQOL was observed, compared with pre-ablation
scores and in all dimensions except Bodily Pain. However, patients without AF during follow-up had significantly
higher absolute HRQOL scores in most dimensions. No differences were seen in most HRQOL dimensions, with
respect to AFL type (paroxysmal, persistent) or duration, whether AFL was first-episode or recurrent, Class I-III drug
dependent, sex, or presence of structural heart disease or tachycardiomyopathy. Patients with persistent AFL showed
the greatest improvement in HRQOL when they also had a ventricular cycle length ≤500 ms. The combination of
recurrent AFL, ventricular cycle length ≤500 ms and structural heart disease led to a significantly greater
improvement in physical HRQOL dimensions than did first-episode AFL, no structural heart disease and ventricular
cycle >500 ms. The only independent factor associated with a greater improvement was structural cardiopathy.
Conclusions: CTI-ablation treatment leads to a significant improvement in HRQOL in patients with typical AFL.
Patients with AF during follow-up show a significantly lower HRQOL at one-year post-ablation. The only
independent risk factor found to be associated with a greater improvement in the physical summary component
was structural cardiopathy.
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Cavotricuspid isthmus (CTI) ablation is a first-line treat-
ment in recurrent typical atrial flutter (AFL). It is
strongly indicated for patients with poor clinical toler-
ance or in whom AFL is a sequela of treatment for atrial
fibrillation (AF) with Class I or III drugs [1-4]. Previous
studies have described a reduction in symptoms and im-
provement in quality of life in AFL patients following
CTI ablation [5-8]. These studies have used the US
population as their reference population, but have not* Correspondence: javiergarciaseara@yahoo.es
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distribution, and reproduction in any mediumadjusted their data for age or sex, factors which signifi-
cantly affect health-related quality of life (HRQOL). We
have recently reported the minimal clinically important
differences which give rise to changes in HRQOL in CTI
ablation patients, thus providing a conceptual basis for
distinguishing whether changes in HRQOL attributable
to treatment are perceptable to the patient [9].
None of these studies, however, have analysed differ-
ences in HRQOL in AFL patients with respect to age,
sex, AFL sub-type (paroxysmal or persistent) or duration,
whether AFL is a first episode or recurrence, presence
or absence of AF, tachycardiomyopathy, anticoagulant
treatment, structural heart disease, or ventricular cycle
length. The aim of our study, therefore, was tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cohort of CTI-dependent AFL patients, before CTI
radiofrequency catheter ablation (basal) and at one-year
follow-up.Patients and methods
Patient population
95 patients were referred sequentially to our Cardiac
Interventional Electrophysiology Laboratory at the Uni-
versity of Santiago de Compostela Hospital, between
January 2003 and March 2005, who fulfilled all the fol-
lowing criteria, were enrolled: a.) over 18 yrs of age; b.)
had at least one AFL episode in the preceding 6 months,
shown by 12-lead ECG; c.) history of lone AFL or pre-
dominant AFL if presenting with concomitant AF, or
AFL resulting from anti-AF treatment with Class I or III
drugs; d.) electrophysiological confirmation of CTI AFL
or CTI permeability if the procedure was carried out in
sinus rhythm. In the latter, the ECG of the clinical epi-
sode had to indicate common typical AFL.
Exclusion criteria were: a.) no CTI-dependent AFL; b.)
cardiac surgery or other cardiac intervention (e.g. coron-
ary angioplasty or pacemaker implantation) in the past
30 days; c.) carrier of implantable cardioverter defibrilla-
tor; d.) life expectancy less than one year; or e.) incom-
plete HRQOL questionnaire.Ablation procedure
All patients had fasted for at least 6 hr and stopped
taking oral anticoagulants at least two days previous to
electrophysiological procedure. A standard quadripolar
catheter (Usci-Bard Inc) was used to map the bundle
of His, a 10-pole catheter (Usci-Bard Inc) to locate the
coronary sinus, and a 12-pole Halo XP catheter (Cor-
dis-Webster Inc) was used to record activation in the
anterolateral aspect of the right atrium. An 8 mm-tip
catheter was used for radiofrequency (RF) ablation. RF
was delivered for 60 s at each location. The maximum
power output was 90 watts, and maximum temperature
was 55°C. CTI-dependence was confirmed by concealed
entrainment if AFL rhythm was either present at the
beginning of the electrophysiological analysis or
induced in the laboratory. If the patient was in sinus
rhythm bidirectional CTI permeability was determined
before ablation.
The objective of the ablation procedure was to effect a
bidirectional conduction block across the CTI [10,11].
Bidirectional block was determined by the sequence of
electrical activity between the right atrium, bundle of
His and coronary sinus following a 600 ms stimulation
in the coronary sinus and in the inferolateral wall of the
right atrium. Persistence of bidirectional CTI conduction
block was tested at 20 min after procedure.HRQOL questionnaire
The Spanish version of the Short-Form-36 (SF-36)
HRQOL questionnaire [12–14] was filled in by all en-
rolled patients before CTI ablation treatment and at
one-year follow-up. This questionnaire consists of 8
scales or dimensions, each containing two or more items
which in turn have a possible score of 0 to 100 (100 sig-
nifying a healthy state) [13]. By combining scores for
each dimension, two summary scores are derived: the
physical component summary (PCS) and the mental
component summary (MCS) [14].
One-year follow-up
All enrolled patients were booked into clinics for follow-
up at 3, 6 and 12 months post-ablation. Any visit to the
Cardiology Department or to the Accident and Emer-
gency Service was registered in the electronic clinical
database. At 6 months post-ablation, any asymptomatic
abnormalities were recorded using an ambulatory Holter
device worn for a period of 7 days.
Statistical analysis
Results of the SF-36 questionnaires were analysed using
Student’s t-test and Mann–Whitney non-parametric
tests, as appropriate. Normality of distribution and
homogeneity of variance were assessed by Kolmogorov-
Smirnov and Levene tests, respectively. Comparisons of
the results of the SF-36 questionnaires before ablation
(basal) and at one-year follow-up were made using Wil-
coxon test for paired data. Differences between basal
and one-year follow-up component summaries were cal-
culated. These covariates were categorized into two
groups: i) improvement or ii) worsening. To investigate
which covariates were associated with improvement in
mental and physical component summaries, two logistic
regression models were performed. P < 0.05 was consid-
ered significant.
Ethical considerations
The study was carried out in accordance with the Princi-
ples of the Declaration of Helsinki (1975) and approved
by the Ethical Committee of Clinical Investigation in




Of 104 patients with AFL referred sequentially to our
Electrophysiology Laboratory, 95 had typical (CTI-
dependent) AFL and were enrolled in the study.
Table 1 shows AFL-related and other characteristics
for the patient population before CTI-ablation treat-
ment. The most common type of AFL was paroxysmal
(56%). Almost 40% of patients had previously received
Table 1 Basal characteristics of enrolled AFL patients
(before CTI-ablation treatment; n = 95)
Age (yr) 64.4 ± 10.6
Males, n (%) 77 (81,1)
COPD, n (%) 20 (21,1)
Hypertension, n (%) 47 (49,5)
Diabetes mellitus, n (%) 19 (20,0)
Obese, n (%) 25 (26,3)
LVEF <50%, n (%) 22 (23,1)
Hypertensive cardiopathy, n (%) 37 (38,9)
Valvulopathy, n (%) 19 (20,0)
Ischaemic heart disease, n (%) 14 (14,7)
Heart Failure, n (%) 18 (18,9)
Dilated cardiomyopathy, n (%) 21 (22,1)
Previous cardiac surgery, n (%) 12 (12,6)
No heart disease, n (%) 20 (21,1)
Cor Pulmonale, n (%) 5 (5,3)
Type of AFL, n (%)
Persistent 53 (55,8)
Paroxysmal 42 (44,2)
Ventricular cycle length, ms 653 ± 223
Paroxysmal 641 ± 260
Persistent 686 ± 192
Duration of AFL, months 12 [3, 48]
AFL episodes, n 2 [1,7]
Previous ECV, n (%) 22 (23,2)
Previous PCV, n (%) 15 (15,8)
Previous anticoagulation treatment, n (%) 55 (57,9)
1 year follow –up anticoagulation treatment n (%) 63 (66,3)
Previous AF, n (%) 41 (43,2)
Class I- III drugs related AFL, n (%) 14 (14,7)
Flecainide 3 (3,1)
Amiodarone 11 (11,6)
Tachycardiomyopathy, n (%) 16 (16,8)
Data are expressed either as mean ± SD or median (1st quartile, 3rd quartile).
COPD: Chronic obstructive pulmonary disease; LVEF: left-ventricular ejection
fraction; AFL: atrial flutter. ECV: electrical cardioversion. PCV: pharmacological
cardioversion.
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concommitant AF, and 44% of patients were undergoing
CTI ablation for their first episode of AFL. There was a
17% incidence of tachycardiomyopathy, and only 58% of
patients had been on anticoagulant medication. 15% of
patients had Class I or III drug-related AFL, with the
majority of cases being attributable to amiodarone.
One-year follow-up
Acute success was achieved in all patients. No patient
died in hospital, but 6 died during the follow-up periodand from the following causes: lung cancer, severe aortic
stenosis, respiratory insufficiency due to COPD, respira-
tory infection and sudden death outside the hospital (2
cases, of which one was due to a pulmonary embolism).
One patient was unable to complete the HRQOL
questionnaire due to a cerebrovascular accident with
neurological sequelae. Thus, 88 patients successfully
completed follow-up and their questionnaires.
13 patients had recurrences of typical AFL (14.6%) be-
fore the end of the follow-up period, of whom 12 under-
went a repeat CTI ablation and the other patient was
treated by electrical cardioversion. 24 patients (25%)
experienced episodes of AF during follow-up, of whom
20 (83%) had previously had AF, and compared with a




A significant improvement in HRQOL was seen at one
year, compared with basal values and with respect to all
dimensions in the SF-36 questionnaire (p < 0.05 all
dimensions; Figure 1).
Socio-demographic variables (age and sex)
No significant differences in HRQOL at one year, com-
pared with basal scores, were found in relation to patient
age. Women showed a significant improvement in the
Emotional Role compared with men. No other gender-
dependent HRQOL differences were recorded at one
year. Neither were any clinical differences observed in
outcome or complications of CTI ablation between men
and women.
AFL characteristics
No differences in HRQOL at one year compared with
basal values were seen with respect to AFL type (parox-
ysmal or persistent), AFL duration, ventricular cycle
length or presence of tachycardiomyopathy. In terms of
number of AFL episodes (first episode or recurrent) a
significant improvement was seen with respect to the
Physical Function dimension in patients with recurrent
compared with first-episode AFL (Table 2a). Patients
with structural heart disease showed a significant im-
provement at one year in terms of the Physical Role di-
mension with respect to no structural heart disease
group (Table 2a). Patients with Class I drug-related AFL
reported similar changes in HRQOL to all other AFL
patients, except in terms of the two dimensions of Gen-
eral Health and Bodily Pain in which the improvements
they reported were significantly less.
Within the persistent AFL group, those with a ven-
tricular cycle ≤500 ms showed a greater improvement in
HRQOL in all dimensions and which reached
80
Basal













































































Figure 1 Box plot depicting HRQOL scores before CTI-ablation treatment (basal) and at one-year follow-up in the whole cohort of AFL
patients (n = 88), for all HRQOL dimensions. Horizontal bars indicate median. PCS: Physical Component Summary; MCS: Mental Component
Summary.
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and Mental Health (Table 2b).
In terms of the dimensions Physical Function, Physical
Role and PCS, the sub-group of patients with recurrent
AFL, structural heart disease and a ventricular cycle
length ≤500 ms showed a significantly greater improve-
ment than first-episode AFL patients without structural
heart disease but with a ventricular cycle >500 ms;
(Table 2c).Atrial fibrillation
Patients with a history of AF gave lower basal scores in
most dimensions of the HRQOL questionnaire than
those with no previous AF, although these differences
were not statistically significant except in General
Health dimension (Table 3). Both AF-in-follow-up and
non-AF-in-follow-up groups recorded significant
improvements in all but one dimension (Bodily Pain) at
one year with respect to basal scores, and several of
these reached p < 0.001. There was no statistically sig-
nificant difference between the two groups (Table 3).
Absolute HRQOL scores at one year, however, were
significantly higher for patients who had not experi-
enced AF during follow-up than for those who had, in
all dimensions except Physical Role, Bodily Pain and
Social Function (Table 3).Anticoagulation treatment
Pre-ablation HRQOL scores were similar regardless of
whether patients were taking basal anti-coagulant medi-
cation. At one-year follow-up, a significant difference
was observed between these two patient groups with re-
spect to one dimension only, namely that of General
Health which was higher in the group not receiving oral
anti-coagulation treatment.
After adjusting for potential confounders, the only fac-
tor found to be associated with a greater improvement
in the physical component (PCS) was the presence of
structural cardiopathy. No other variable was found to
be associated with improvement in the summary compo-
nents at one-year follow-up (Table 4).
Discussion
The aim of the current study was to identify demo-
graphic or clinical parameters associated with the great-
est improvement of HRQOL scores in patients with
typical AFL undergoing CTI catheter ablation. Thus we
have analysed, for the first time, changes in HRQOL
scores before ablation and at one-year follow-up, in
terms of several patient sub-groups. Taken as a whole,
the population of typical AFL patients that we studied
showed a clinically significant improvement in HRQOL
one year after undergoing CTI ablation [9]. This result
was notable given that the cohort included patients with
Table 2 Differences in HRQOL at one-year follow-up after CTI-ablation treatment compared with basal scores in
different sub-groups of AFL patients
A. Differences in HRQOL with respect to presence of structural heart disease and number of AFL episodes. Data are expressed as
mean± SD; *p < 0.05. AFL: Atrial flutter
Structural heart disease N° of AFL Episodes
Yes No p 1 episode > 1episode p
(n= 68) (n = 20) (n = 37) (n = 51)
Physical Function 26.5 ± 20.8 17.5 ± 20.9 0.10 18.4 ± 17.5 28.8 ± 22.4 0.02*
Role Physical 49.8 ± 46.9 28.7 ± 37.4 0.04* 40.5 ± 40.1 48.3 ± 49.4 0.41
Bodyly Pain 8.6 ± 30.5 14.0 ± 36.5 0.55 9.1 ± 30.5 10.3 ± 33.1 0.85
General Health 16.1 ± 20.3 12.6 ± 15.9 0.42 13.2 ± 22.8 16.9 ± 16.5 0.40
Vitality 27.4 ± 23.8 16.7 ± 23.7 0.08 24.3 ± 21.7 25.5 ± 25.8 0.81
Social Function 14.8 ± 25.6 22.1 ± 23.3 0.24 18.4 ± 26.1 15.2 ± 24.5 0.56
Role Emotional 29.9 ± 39.5 36.7 ± 44.5 0.54 30.6 ± 38.0 32.0 ± 42.7 0.87
Mental Health 18.5 ± 23.7 15.4 ± 21.4 0.57 16.5 ± 23.0 18.7 ± 23.3 0.66
B. Differences in HRQOL in persistent AFL with respect to ventricular cycle length. Data are expressed as mean± SD; *p < 0.05; **p< 0.01
Ventricular cycle length
≤500 ms (n= 10) >500 ms (n = 30) p
Physical Function 32.5 ± 30.9 21.2 ± 16.5 0.17
Role Physical 71.9 ± 36.4 36.6 ± 44.3 0.04*
Bodily Pain 20.5 ± 36.2 5.5 ± 27.1 0.20
General Health 34.3 ± 15.0 11.0 ± 22.4 0.009**
Vitality 45.6 ± 27.3 24.3 ± 23.9 0.04*
Social Function 26.6 ± 33.7 18.9 ± 25.8 0.40
Role Emotional 50.0 ± 39.8 29.8 ± 39.9 0.21
Mental Health 35.5 ± 21.4 16.6 ± 21.5 0.03*
C. Differences in HRQOL with respect to combined characteristics. Data are expressed as mean± SD; *p < 0.05. PCS: Physical Component
Summary; MCS: Mental Component Summary; AFL: atrial flutter
Recurrent AFL+≤500 ms cycle
+ structural heart disease (n = 12)
1st episode AFL + >500 ms cycle
+ no structural heart disease (n = 4)
p
Physical Function 38.7 ± 24.1 12.5 ± 17.1 0.03
Physical Role 60.4 ± 40.5 0.0 ± 0.0 0.02*
Bodily Pain 6.3 ± 28.8 −6.5 ± 37.2 0.57
General Health 24.1 ± 20.5 10.5 ± 17.0 0.41
Vitality 31.2 ± 28.0 16.2 ± 26.2 0.34
Social Function 21.9 ± 28.2 23.1 ± 21.7 0.75
Emotional Role 33.3 ± 44.9 41.7 ± 50.0 0.94
Mental Health 21.3 ± 24.6 23.0 ± 18.3 0.94
PCS 35.4 ± 27.7 −8.2 ± 22.2 0.02*
MCS 20.2 ± 38.3 40.4 ± 38.3 0.41
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AFL (44%). After adjusting for age, sex, and other
cardiovascular-related parameters, the presence of struc-
tural cardiopathy was associated with an improvement
in the physical summary component that was 5.8 greater
than that of the absence of structural cardiopathy, and
the only variable that made a difference that was statisti-
cally significant.The recurrence rate of AFL at one year was 14.6%, a
slightly higher level than reported for the majority of
other patient series (20% at 1 year, [5,15] 10%[16] and
6.3% at 16 meses, [17] 4.8% at 21 meses [18]). One po-
tential partial explanation would be that while a 8–mm-
tip catheter was used in 93 patients (97.9%), an
irrigated-tip catheter was used in the remaining two
patients (2.1%), since it is known that an irrigated tip
Table 3 Differences in HRQOL with respect to the presence of AF in Follow-up
AF in Follow-up No AF in Follow-up
(n = 23) (n = 65)
Basal 1-year FU Basal 1- year FU
Physical Function [ns] 56.7 ± 23.2 83.0 ± 14.2♦♦ 61.9 ± 23.8 86.1 ± 15.8♦♦
Physical Role [**] 23.9 ± 36.5 60.4 ± 39.2♦♦ 34.1 ± 42.2 82.3 ± 30.8♦♦
Bodily Pain [ns] 57.5 ± 33.9 69.7 ± 30.0 72.7 ± 30.7 81.8 ± 27.4
General Health [**] 34.7 ± 20.1 46.1 ± 21.3♦ 45.8 ± 17.2♠ 62.8 ± 18.9♦
Vitality [*] 36.7 ± 23,8 58.9 ± 21.1♦ 44.7 ± 24.4 71.0 ± 23.2♦♦
Social Function [ns] 67.2 ± 29.8 83.1 ± 26.3♦♦ 75.3 ± 28.2 91.7 ± 18.4♦♦
Emotional Role [*] 43.5 ± 45.4 76.8 ± 41.9♦♦ 62.1 ± 42.9 92.8 ± 21.6♦♦
Mental Health [**] 52.0 ± 24.4 64.9 ± 18.7♦ 57.3 ± 23.0 76.7 ± 17.4♦♦
PCS [*] 42.1 ± 27.0 62.9 ± 22.9♦♦ 50.6 ± 27.3 75.0 ± 26.9♦♦
MCS [*] 47.8 ± 34.8 67.3 ± 32.8♦♦ 59.1 ± 33.1 79.7 ± 20.9♦♦
HRQOL scores at basal and at one-year follow-up in patients with and without AF during follow-up. Data are expressed as mean ± SD. PCS: Physical Component
Summary; MCS: Mental Component Summary; AF: atrial fibrillation. FU: Follow-up.
[*] p < 0.05, [**] p < 0.01, [ns] no significant, for the differences in HRQOL at one-year follow-up between patients with or without AF during follow-up.
♦ p< 0.05; ♦♦ p< 0.01: p-values for the differences at one-year follow-up compared with basal values in each group.
♠ p = 0.02 for the differences at basal between patients with or without AF during follow-up. No significant differences in any of HRQOL remaining dimensions at
basal between the two groups.
No significant difference were found for HRQOL differences values (one year follow-up - basal) between patients with or without AF during follow-up.
García Seara et al. Health and Quality of Life Outcomes 2012, 10:90 Page 6 of 9
http://www.hqlo.com/content/10/1/90produces more profound lesions than an 8- mm- tip
catheter. However, to date no associated differences in
outcome have been demonstrated either acutely [16,19]
or in the longer term [17] after treatment of CTI-
dependent AFL with an irrigated-tip or 8-mm- tip cath-
eter. We therefore conclude that our increased recurrence
levels were probably due to factors other than catheter
tip, and most likely related to CTI morphology.’
Patients who developed AF during follow-up also
showed a significant improvement in HRQOL at one
year, except in the dimension of Bodily Pain. Although
the group who developed AF during follow-up showed a
smaller improvement in HRQOL with respect to the
group that did not develop AF, the difference between
the two groups did not approach significance in any di-
mension. Without further analysis, this result contrasts
with that of Lee et al [8] in which a history of AF was
the only factor associated with reduced improvement of
HRQOL in patients with typical AFL undergoing CTI
ablation. However, when we took into account HRQOL
at one-year follow-up we also found in our cohort that
for most dimensions final scores were significantly better
in patients who had not experienced AF during follow-
up than in those who had. These data suggest that the
differences seen in basal HRQOL (lower in patients with
a history of AF) maintained and formed a component of
the scores obtained at one year after CTI catheter abla-
tion (smaller improvement in patients experiencing AF
during follow-up), thus accounting for the differences
seen at one year in most of dimensions approaching or
reaching significance. Interpreted thus, our results forHRQOL at one-year follow-up agree more closely with
those of Lee et al [8].
A long-term (27 months) benefit in quality of life in
patients undergoing CTI ablation with a history of AF
has previously been reported by Anselme [20]. Those
results are similar to ours with respect to the 8 dimen-
sions of the SF36 questionnaire, showing a significant
improvement in all items except for Bodily Pain. In
that study, the improvement was smaller in patients
with a history of AF than in those without, but the dif-
ference between those two groups was not significant.
However, in our cohort, basal scores were significantly
lower overall, and especially in patients who had pre-
sented AF during follow-up. In Anselme’s cohort,
moreover, patients with a history of AF also had higher
basal scores than those without, in the majority of
items.
Whilst the presence of AF reduced the benefit of CTI
ablation in typical AFL patients, the AF group did still
show a significant improvement in HRQOL at one year.
Moreover, the post-ablation rate of AF appears to be
time-dependent with previous figures for incidence of
AF during three-year follow-up varying widely, from
15% [21] to 82% [22]. This suggests that typical-AFL
populations differ with respect to incidence of AF, and
raises the question of how CTI ablation in AFL can be
so effective within a context of such a frequent second-
ary arrhythmia. Willems et al have found an improve-
ment in quality of life in a cohort of patients undergoing
CTI ablation for typical AFL and with an AF incidence
of 60% at 2 years [23].
Table 4 Associated factors with improvement in physical and mental component summaries at one-year follow-up
PCS MCS
OR (95% CI) p-value OR (95% CI) p-value
Age, yr 0.95 (0.98, 1.02) 0.126 1.03 (0.97, 1,09) 0.337
Gender 1.37 (0.25, 7.37) 0.714 0.93 (0.19, 4.48) 0.923
Structural heart disease 5.83 (1.14, 29.7) 0.034 1.58 (0.36, 6.92) 0.545
AF at follow-up 2.96 (0.38, 22.9) 0.298 1.49 (0.34, 6.55) 0.596
AFL recurrence 0.29 (0.05, 1.77) 0.178 5.12 (0.51, 51.2) 0.164
> 1 episode of AFL 1.66 (0.45, 6.14) 0.447 0.34 (0.11, 1.11) 0.075
Ventricular cycle length 1.51 (0.36, 6.30) 0.573 1.60 (0.49, 5.28) 0.439
PCS means physical component summary; MCS, mental component summary; AF, atrial fibrillation; AFL, atrial flutter; OR, odds ratio; 95%CI, 95% confidence
interval.
Codes used in the logistic regression analysis: Gender (0, female; 1, male). Structural heart disease (0, no; 1, yes). AF at follow-up (0, no; 1, yes). AFL recurrence (0,
no; 1, yes). > 1 episode of AFL (0, no; 1, yes). Ventricular cycle length (0, > 500 ms; 1, < 500 ms).
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to be complex, but the following factors should be
considered.
First, AF is better tolerated than AFL. AFL normally
presents with a conduction ratio of 2:1 or 3:1, producing
heart rates between 150 lpm and 130 lpm. The fact that
it is also more difficult to achieve adequate pharmaco-
logical control of heart rate in AFL than in AF could ex-
plain why symptoms in AFL patients are generally more
severe. In a cohort of patients with AF being treated
with anti-arrhythmic drugs the presence of AFL during
follow-up was associated with a lower rate of return to
sinus rhythm due to anti-arrhythmic drugs and with a
higher number of hospitalisations than AF recurrence.
In the same population there was an 8.5% incidence of
AFL having a 1:1 conduction ratio, a highly symptomatic
form of AFL [24]. Therefore, AFL appears to be an
arrhythmia with a higher impact on HRQOL than that
of AF because it is more symptomatic, more refractory
to pharmacological treatment – in terms of control of
both heart rate and rhythm – and leads to a greater
number of hospitalisations than AF.
Second, reduction of number of symptomatic palpita-
tion episodes and AF burden following ablation for AFL.
A reduction in the number of AF episodes post-ablation
has been widely reported [16,25,26]. One explanation
could be the elimination of AFL as a trigger of AF
events. It has also been suggested that normalisation of
the effective refractory period and inverse electrical re-
modelling in the atrium reduce the frequency of AF
[27]. In our patient cohort, the recorded incidence of AF
at one-year follow-up was reduced from 43% basal to
25%. This reduction should, however, be interpreted
with caution as AF diagnosis was based on symptoms
and events registered by Holter monitoring over the
one-year period. A more rigorous approach might be to
monitor and diagnose oligosymptomatic episodes, and/orto have a longer follow-up period in which to gather
data on the development of AF in post-ablation patients.
Ellis et al [22] have reported an incidence in post-
ablation AF of up to 82% at 3 years and 3 months. Simi-
larly, Chinitz et al [28] have reported an occurence of
AF of 50% at a follow-up of 2.5 years in a cohort of
patients with typical isolated AFL undergoing CTI abla-
tion. More recently, a recurrence of AF has been
reported in 90% of patients receiving hybrid treatment
(ablation for AFL+ antiarrhythmic treatment for AF) at
5-year follow-up [29]. It seems likely that AFL and AF
constitute different electrocardiolographic expressions of
a common atrial disease and that CTI ablation does not
eliminate the risk of subsequent AF [30].
Patients who had experienced only a single AFL event
showed a similar improvement in HRQOL to those with
recurrent AFL, although the latter group showed a ten-
dency towards increased improvement in the physical
dimensions. The benefit of CTI ablation over amiodar-
one treatment in patients who had experienced only a
single episode of AFL had been described previously
[31]. This datum is important because patients with a
single AFL event are usually treated more conservatively,
on the assumption that they will benefit less from abla-
tion therapy and recurrence will be delayed.
No differences in HRQOL were seen with respect to
ventricular cycle length of ≤500 ms or >500 ms. Neither
were any differences seen in relation to presence or ab-
sence of tachycardiomyopathy, which makes sense in the
absence of ventricular-cycle-related differences. Our ob-
servation that patients who had presented with persist-
ent AFL and a ventricular cycle of ≤500 ms (heart rate
≥120 lpm) showed a significant improvement in four
HRQOL dimensions (compared with patients with per-
sistent AFL and ventricular cycle of >500 ms), however,
demonstrates that when AFL is persistent ventricular
cycle length can affect HRQOL.
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binations of characteristics (i. persistent AFL + ventricu-
lar cycle ≤500 ms; ii. structural heart disease + ventricular
cycle ≤500 ms + recurrent AFL) revealed greater differ-
ences, particularly in relation to physical dimensions.
While these differences are potentially important, the
fact that the number of cases in each group was low
would have reduced the capacity for statistical tests to
show significant differences in other dimensions. Indeed,
it seems possible that the combination of structural heart
disease, ventricular cycle ≤500 ms and recurrent AFL will
be a better predictor of improvement in HRQOL scores
following CTI ablation than will each of those factors
individually.
Limitations
The majority of studies using the SF-36 questionnaire
have observed ceiling effect (more than 15% of patients
had the maximum value for a dimension) on the dimen-
sions of Physical Role and Emotional Role. In our cohort
we have observed a ceiling effect in the basal dimensions
Physical Role, Bodily Pain, Social Function and Emo-
tional Role and at one-year follow-up in the same
dimensions and additionally in Physical Function. There-
fore the presence of a ceiling effect might have caused
an underestimation of the size of change in HRQOL
over the one-year follow-up period. In three dimensions
(General Health, Vitality and Mental Health) a ceiling ef-
fect was not seen, and thus the values obtained in those
dimensions were particularly valuable in assessing im-
provement in HRQOL at one year.
Other limitations were the following. a.) Because of
the advanced age and comorbidities in our population,
we lost some patients during follow-up due to death
or incapacity to complete the second questionnaire at
one year. b.) The low number of patients we recruited.
c.) The observational approach we used. Because we
did not randomly assign patients to treatment and pla-
cebo groups, we could not make inferences about
cause and effect. It will therefore be important to carry
out controlled studies in the future. d.) We used only
a general type of questionnaire to evaluate quality of
life, and not one designed for the context of cardiac
arrhythmias [32,33] and e) A 7-day Holter recording is
a rather limited method to assess AF burden. An
implantable loop recorder would have provide more
accuracy [34].
Conclusions
In conclusion, the main finding of our analysis of
changes in HRQOL scores of typical AFL patients one
year after CTI ablation treatment, in relation to age, sex
and several relevant cardiovascular parameters, was that
improvement in HRQOL was most strongly associatedwith absence of AF. We also found the presence of
structural cardiopathy to be independently associated
with a greater improvement in in the physical summary
component.
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